## Highlights of This Issue

### SPECIAL FEATURES

- **The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer**
  Fred R. Hirsch, Murry W. Wynes, David R. Gandara, and Paul A. Bunn, Jr. See article p. 4938

- **Comparing Survival Curves Using an Easy to Interpret Statistic**
  Kenneth R. Hess

- **Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer**
  Andrew C. Hsieh and Davide Ruggero

- **Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary**
  Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghuo Tang, W. David McGuinn, Jr., S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Julin Justice, and Richard Pazdur

- **Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer**
  Charlotte E. Edling, Federico Selvaggi, Richard Buus, Tania Maffucci, Pierluigi Di Sebastian, Helmut Friess, Paolo Innocenti, Hemant M. Kocher, and Marco Falasca

## Cancer Therapy: Preclinical

- **EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration**
  Yuichi Sakairi, Takahiro Nakajima, Kazuhiro Yasufuku, Dai Iikebe, Hajime Kagayama, Manabu Soda, Kengo Takeuchi, Makiko Itami, Toshikiko Iizasa, Ichiro Yoshino, Hiroyuki Mano, and Hideki Kimura

- **Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors**
  Kevin O. Hicks, Bronwyn G. Siim, Jagdish K. Jaiswal, Frederik B. Pruijn, Annie M. Fraser, Rita Patel, Alison Hog, H.D. Sarath Liyanage, Mary Jo Doria, J. Martin Brown, William A. Denny, Michael P. Hay, and William R. Wilson

- **Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors**
  Roberta Irapoli, Elena Tamborini, Emanuela Virdis, Ezio Bello, Eva Tarantino, Sergio Marchini, Federica Grosso, Roberta Sanfilippo, Alessandro Gronchi, Juan Carlos Tercero, Gabriella Peloso, Paolo Casali, Silvana Pilotti, and Maurizio D’Incalci

- **Radiation-Guided Drug Delivery to Mouse Models of Lung Cancer**
  Ghazal Hariri, Heping Yan, Hailun Wang, Zhaozhong Han, and Dennis E. Hallahan

- **A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes**
  Marci D. Jones, Julie C. Liu, Thomas K. Barthel, Sadiq Hussain, Erik Lovria, D Mengfeng Cheng, Jesse A. Schoonmaker, Sudhanshu Mulay, David C. Ayers, Mary L. Bouxsein, Gary S. Stein, Siddhartha Mukherjee, and Jane B. Lian
Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin

Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors
Tetsuya Hamaguchi, Toshihiko Doi, Takako Eguchi-Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Nozomu Fuse, Atsushi Ohtsu, Shin-ichi Matsumoto, Masaya Takanashi, and Yasuhiro Matsumura

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
Sagar Lonial, Jonathan Kaufman, Mourad Tighiouart, Ajay Nooka, Amelia A. Langston, Leonard T. Heffner, Claire Torre, Stephanie McMillan, Heather Renfroe, R. Donald Harvey, Mary J. Lechowicz, H. Jean Khoury, Christopher R. Flowers, and Edmund K. Waller

 Correction: Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplicated in Breast Cancer 1 in Normal and Malignant Human Breast Tissue
Chang-Qi Zhu, Dan Strumpf, Chun-Yan Li, Qing Li, Ni Liu, Sandy Der, Frances A. Shepherd, Ming-Sound Tsao, and Igor Jurisica
ABOUT THE COVER

A humanized, monoclonal antibody against PDGFRα was able to inhibit both early colonization of the bone and late progression of skeletal lesions in a murine model of prostate cancer metastasis. The image shows a metastatic tumor produced in the proximal femur by green fluorescent PC3-ML cells, four weeks after being inoculated via the hematogenous route. For further details, please see the article by Russell and colleagues on page 5002 of this issue.